Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 7, 2006, Pages 953-964

  Hemphill, Andrew ^a   Mueller, Joachim ^a   Esposino, Marco ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anaerobic bacteria; Cestodes; Cryptosporidium; Giargia; Intestinal nematodes; Nitazoxaninde; Thiazolides; Trematodes

Indexed keywords

2 ACETYLOLOXY N (5 NITRO 2 THIAZOLYL)BENZAMIDE; ALANINE AMINOTRANSFERASE; ALBENDAZOLE; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; GAMMA INTERFERON ANTIBODY; IVERMECTIN; METRONIDAZOLE; NITAZOXANIDE; NITROTHIAZOLE DERIVATIVE; OMEPRAZOLE; PAROMOMYCIN; PEGINTERFERON; PHENYTOIN; PLACEBO; PRAZIQUANTEL; RIBAVIRIN; SULFONAMIDE; THIAZOLE DERIVATIVE; THIAZOLIDE DERIVATIVE; TIZOXANIDE; TRICLABENDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AFRICA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAEROBIC BACTERIUM; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CESTODIASIS; CLINICAL TRIAL; COLITIS; CROHN DISEASE; CRYPTOSPORIDIOSIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; EYE DISEASE; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GIARDIASIS; HEADACHE; HELMINTHIASIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCREASED APPETITE; INFECTION; MALAISE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PROTOZOAL INFECTION; PRURITUS; REVIEW; RHINITIS; SALIVARY GLAND DISEASE; SOUTH AMERICA; SOUTHEAST ASIA; SUSPENSION; SWEATING; TREMATODIASIS; VIRUS INFECTION; VOMITING;

ANIMALS; ANTI-INFECTIVE AGENTS; GASTROINTESTINAL DISEASES; HUMANS; THIAZOLES;

EID: 33646575909     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.7.953     Document Type: Review

References (61)

1. GILLES HM, HOFFMAN PS: Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. (2002) 18:95-97.
2. FOX LM, SARAVOLATZ LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Inf. Dis. (2005) 40:1173-1180.
3. WHITE CA Jr: Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev. Anti Infect. Ther. (2004) 2:43-49.
4. ROSSIGNOL JF, CAVIER R: New derivative of 2-benzamido-5-nitrothiazoles. Chem. Abstr. (1975) 83:28216.
5. ROSSIGNOL JF, MAISONNEUVE H: Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana. Am. J. Trop. Med. Hyg. (1984) 33:511-512.
6. ROSSIGNOL JF, MAISONNEUVE H, CHO YW: Nitroimidazoles in the treatment of trichomoniasis, giardiasis and amoebiasis. Int. J. Clin. Pharmacol. Ther. Toxicol. (1984) 22:63-72.
7. ABAZA H, EL-ZAYADI A, KABIL SM, RIZK H: Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: a report on 546 patients in Egypt. Curr. Ther. Res. (1998) 59:116-121.
8. ORTIZ JJ, AYOUB A, GARGALA G, CHEGNE NL, FAVENNEC L: Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment. Pharmacol. Ther. (2001) 15:1409-1415.
9. ROSSIGNOL JF, AYOUB A, AYERS MS: Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. (2001) 184:103-106.
10. ROSSIGNOL JF, AYOUB A, AYERS MS: Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or Entamoeba dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. (2001) 184:381-384.
11. ROSSIGNOL JF, ABAZA H, FRIEDMAN H: Successful treatment of human fascioliasis with nitazoxanide. Trans. R. Soc. Trap. Med. Hyg. (1998) 92:103-104.
12. ROSSIGNOL JF, KABIL SM, SAID M, SAMIR H, YOUNIS AM: Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol. (2005) 3:987-991.
13. ADAGU IS, NOLDER D, WARHURST D, ROSSIGNOL JF: In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. (2002) 49:103-111.
14. CEDILLO-RIVERA R, CHAVEZ B, GONZALES-ROBLES A, TAPIA A, YEPEZ-MULIA L: In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J. Eukaryot. Microbiol. (2002) 49:201-208.
15. STETTLER M, FINK R, WALKER M et al.: In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob. Agents Chemother. (2003) 47:467-474.
16. STETTLER M, ROSSIGNOL JF, FINKA R et al.: Secondary and primary murine alveolar echinococcosis: combinedalbendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int. J. Parasitol. (2004) 34:615-624.
17. WALKER M, ROSSIGNOL JF, TORGERSON P, HEMPHILL A: In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J. Antimicrob. Chemother. (2004) 54:609-616.
18. ESPOSITO M, STETTLER R, MOORES S et al.: In vitro efficacies of nitazoxanide and other thiazolides against Neospora caninum reveal anti-parasitic activity independent of the nitro group. Antimicrob. Agents Chemother. (2005) 49:3715-3723.
19. GARGALA G, BAISHANBO A, FAVENNEC L, FRANCOIS A, BALLET JJ, ROSSIGNOL JF: Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxy-isoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development. Antimicrob. Agents Chemother. (2005) 49:4628-4634.
20. DUBREUIL L, HOUCKE I, MOUTON Y, ROSSIGNOL JF: In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. (1996) 40:2266-2270.
21. MEGRAUD F, OCCHIALINI A, ROSSIGNOL JF: Nitazoxanide: a potential drug for eradication of Helicobacter pilori with no cross-resistance to metronidazole. Antimicrob. Agents Chemother. (1998) 42:2836-2840.
22. MCVAY CS, ROLFE RD: In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. (2000) 44:2254-2258.
23. COHEN SA: Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective. Curr. Med. Res. Opin. (2005) 21:999-1004.
24. MUELLER J, RUEHLE G, MUELLER N, ROSSIGNOL JF, HEMPHILL A: In vitro effects of thiazolides on Giardia lamblia WB Clone C6 cultured axenically and in coculture with Caco2 Cells. Antimicrob. Agents Chemother. (2006) 50:162-170.
25. SAMUELSON J: Why metronidazole is active against both bacteria and parasites. Antimicrob. Agents Chemother. (1999) 43:1533-1541.
26. SISSON G, GOODWIN A, RAUDONIKIENE A et al.: Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. (2002) 46:2116-2123.
27. YAMAMOTO Y, HAKKI A, FRIEDMAN H et al.: Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with antivacuolating toxin activity. Chemotherapy (1999) 45:303-312.
28. UPCROFT JA, CAMPBELL RW, BENAKLI K, UPCROFT P, VANELLE P: Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob. Agents Chemother. (1999) 43:73-76.
29. ESPOSITO M, MUELLER N, ROSSIGNOL JF, HEMPHILL A: In vitro efficacy of nitazoxanide and other thiazolides against intracellular Neospora caninum tachyzoites reveals anti-parasitic activity independent of the nitro group. Proceedings of the 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington DC, USA (11-15 December 2005) Presentation 23.
30. LLOYD D, HARRIS JC, BIAGINI GA et al.: The plasma membrane of microaerophilic protists: oxidative and nitrosative stress. Microbiology (2004) 150:1183-1190.
31. SANDHU H, MAHAJAN CR, GANGULY NK: Flowcytometric assessment of the effect of drugs on Giardia lamblia trophozoites in vitro. Mol. Cell Biochem. (2004) 265:151-160.
32. DURRANT WE, DONG X: Systemic acquired resistance. Ann. Rev. Phytopathol. (2004) 42:185-209.
33. VANE JR: The fight against rheumatism: From willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol. (2000) 51:573-586.
34. MUELLER J, RUEHLE G, MUELLER N, ROSSIGNOL JF, HEMPHILL A. Effects of nitazoxanide and other thiazolides on Giardia lamblia growth, morphology and ultrastructure. Proceedings of the 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington DC, USA (11-15 December 2005) Presentation 488.
35. ATHERTON RD: Mechanisms of action of nitazoxanide and related drugs against helminths. Thesis submitted for the degree of Doctor of Philosophy of the University of London (2003).
36. STOCKIS A, ALLEMON AM, DEBRUYN S, GENGLER C: Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int. J. Clin. Pharmacol. Ther. (2002) 40:213-220.
37. BROEKHUYSEN J, STOCKIS A, LINS RL, DE GRAEVE J, ROSSIGNOL JF: Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. (2000) 38:387-394.
38. STOCKIS A, DEBRUYN S, GENGLER C, ROSILLON D: Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol. Ther. (2002) 40:221-227.
39. PARASHAR P, ARYA R: Nitazoxanide. Indian Pediatr. (2005) 42:1161-1165.
40. THEODOS CM, GRIFFITHS JK, D'ONFRO J, FAIRFIELD A, TZIPORI S: Efficacity of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. (1998) 42:1959-1965.
41. GIACOMETTI A, CIRIONI O, BARCHIESI F, ANCARANI F, SCALISE G: Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J. Antimicrob. Chemother. (2000) 45:453-456.
42. GARGALA G, DELAUNAY A, LI X, BRASSEUR P, FAVENNEC L, BALLET JJ: Efficacity of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infcted HCT-8 enterocytic cells. J. Antimicrob. Chemother. (2000) 46:57-60.
43. BLAGBURN BL, DRAIN KL, LAND TM et al.: Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrob. Agents Chemother. (1998) 42:2877-2882.
44. LI X, BRASSEUR P, AGNAMEY P et al.: Longlasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitol. (2003) 50:19-22.
45. DOUMBO O, ROSSIGNOL JF, PICHARD E et al.: Nitazoxanide in the treatment of cryposporidial diseases and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. (1997) 56:637-639.
46. ROSSIGNOL JF, HIDALGO H, FEREGRINO M et al.: A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. (1998) 92:663-666.
47. AMADI B, MWIYA M, MUSUKU J et al.: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet (2002) 360:1375-1380.
48. BAISHANBO A, GARGALA G, DELAUNAY A, FRANCOIS A, BALLET JJ, FAVENNEC L: Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils. Infect. Immun. (2005) 73:5252-5255.
49. ORTIZ JJ, LOPEZ CHEGNE N, GARGALA G, FAVENNEC L: Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:193-196.
50. DAVILA-GUTIERREZ CE, VASQUEZ C, TRUJILLO-HERNANDEZ B, HUERTA M: Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am. J. Trop. Med. Hyg. (2002) 66:251-254.
51. RODRIGUEZ-GARCIA R, RODRIGUEZ-GUZMAN LM, CRUZ DEL CASTILLO AH: Effectiveness and safety of mebendazole compared to nitazoxanide in the treatment of Giardia lamblia in children. Rev. Gastroenterol. Mex. (1999) 64:122-126.
52. ABBOUD P, LEMEE V, GARGALA G et al.: Successful treatment of metronidazole-and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. (2001) 32:1792-1794.
53. ROMERO CABELLO R, GUERRORO LR, MUNOZ GARCIA MR, GEYNE CRUZ A: Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. (1997) 91:701-703.
54. DIAZ E, MONDRAGON J, RAMIREZ E, BERNAL R: Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am. J. Trop. Med. Hyg. (2003) 68:384-385.
55. BICART-SEE A, MASSIP P, LINAS MD, DATRY A: Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob. Agents Chemother. (2000) 44:167-168.
56. KABIL SM, ASHRY EE, ASHRAF NK: An open-label clinical study of nitazoxanide in the treatment of human fascioliasis. Curr. Ther. Res. (2000) 61:339-345.
57. FAVENNEC L, JAVE ORTIZ J, GARGALA G, LOPEZ CHEGNE N, AYOUB A, ROSSIGNOL JF: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of facioliasis in adults and children from northern Peru. Aliment. Pharmacol. Ther. (2003) 17:265-270.
58. GUTTNER Y, WINDSOR HM, VILALA CH, DUSCI L, MARSHALL BJ: Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob. Agents Chemother. (2003) 47:3780-3783.
59. STOCKIS A, DEROUBAIX X, LINS R, JEANBAPTISTE B, CALDERON P, ROSSIGNOL JF: Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int. J. Clin. Pharmacol. Ther. (1996) 34:349-351.
60. UTZINGER J, KEISER J: Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin. Pharmacother. (2004) 5:263-285.
61. NAGULESWARAN A, SPICHER M, ROSSIGNOL JF, HEMPHILL A: Investigations on the use of thiazolides for treatment of Echinococcus granulosus infections. Proceeding of the 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington DC, USA (11-15 December 2005).